The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma. Patients and Methods: Patients were randomly assigned to paclitaxel 135 mg/m 2 over 24 hours plus Cis 50 mg/m 2 day 2 every 3 weeks (PC, reference arm); vinorelbine 30 mg/m 2 days 1 and 8 plus Cis 50 mg/m 2 day 1 every 3 weeks (VC); gemcitabine 1,000 mg/m 2 day 1 and 8 plus Cis 50 mg/m 2 day 1 every 3 weeks (GC); or topotecan 0.75 mg/m 2 days 1, 2, and 3 plus Cis 50 mg/m 2 day 1 every 3 weeks (TC). Survival was the primary end point with a 33% improvement relative to PC considered important (85% power, alpha = 5%). Quality-of-life data were prospectively collected. Results: A total of 513 patients were enrolled when a planned interim analysis recommended early closure for futility. The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC. The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC. Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively. The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia. Conclusion: VC, GC, and TC are not superior to PC in terms of overall survival (OS). However, the trend in RR, PFS, and OS favors PC. Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
New Tables for Multiple Comparisons with a Control
Dunnett, C. W. (1964) · Biometrics · doi:10.2307/2528490 · Cited by 3,113
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Self-citationLong, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.021 · Cited by 556
Self-citationMonk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Self-citationMonk, B. J., Tewari, K. S., & Koh, W.-J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8324 · Cited by 261
Self-citationMonk, B. J., Huang, H. Q., Cella, D. F., & Long, H. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.522 · Cited by 131
Self-citationGynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer
Tewari, K. S., & Monk, B. J. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0007-z · Cited by 103
Self-citationMonk, B. J., Tian, C., Rose, P. G., & Lanciano, R. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.027 · Cited by 98
Self-citationStopping when the experimental regimen does not appear to help
Wieand, S., Schroeder, G. S., & O'Fallon, J. R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131321 · Cited by 92
Morris, M., Blessing, J. A., Monk, B. J., McGehee, R., & Moore, D. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.006 · Cited by 57
Self-citationMonk, B. J., & Tewari, K. S. (2007) · Elsevier eBooks · doi:10.1016/b978-032303978-9.50006-x · Cited by 25
Self-citationPlaxe, S. C., Brooks, S. E., Tian, C., Bloss, J. D., Moore, D. H., & Long, H. J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.04.038 · Cited by 10
Cited by
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Self-citationBhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12611 · Cited by 1,134
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Tewari, K. S., Salman, P., Hoyos Usta, E., Yañez, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112435 · Cited by 1,067
Self-citation
Metadata
- Authors
- Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-01
- Volume
- 27
- Issue
- 28
- Pages
- 4649-4655
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118508302
- Cited by
- 693
- References
- 18
- FWCI
- 34.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.